Monday, 29 September 2014
ESMO 2014 press release: New data on combination treatments for melanoma
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment